Table 1.

Primary Efficacy Endpoints: Results From Four Placebo-Controlled Studies

Study No.	Primary Endpoint	Least Squares Mean (SE) Difference from Placebo in Change From Baseline
		Lurasidone 40 mg/day	Lurasidone 80 mg/day	Lurasidone 120 mg/day	Olanzapine 15 mg/day
1	BPRSd	−5.6* (2.1)	—	−6.7* (2.2)	—
2	BPRSd	—	−4.7*(1.8)	—	—
3	PANSS	−9.7* (2.9)	—	−7.5* (3.0)	−12.6* (2.8)
4	PANSS	−2.1 (2.5)	−6.4* (2.5)	−3.5 (2.5)

^*Adjusted P value, < 0.05 (except for olanzapine).

BPRSd = Brief Psychiatric Rating Scale, derived; PANSS = Positive and Negative Syndrome Scale; SE = standard error.

Data from Latuda product information, 2010.¹⁵